Anacor Pharmaceuticals ANAC today announced positive
preliminary results from the first of two Phase 3 trials of tavaborole,
its topical anti-fungal for onychomycosis, a fungal infection of the
nail and nail bed that affects approximately 35 million people in the
United States. Tavaborole achieved a high degree of statistical
significance on all primary and secondary endpoints.
Primary Endpoint
In this first Phase 3 study (known as Study 301), 6.5% of patients
treated with tavaborole met the primary endpoint of “complete cure”
vs. 0.5% of patients treated with vehicle (p=0.001) at week 52.
“Complete cure” is a composite endpoint
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in